Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283315 | 0.82 | RIOK2 (0.50) | PDPK1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL2283312 | 0.82 | RIOK2 (0.50) | PDPK1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL28351134 | 0.77 | LMNA (0.54) | PDPK1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL28351133 | 0.77 | LMNA (0.54) | PDPK1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL7897474 | 0.72 | ALDH1A1 (0.50) | PDPK1SMN1; SMN2NPC1RAB9ARIOK2 | |
| SCHEMBL9136327 | 0.71 | PDPK1 (0.41) | PDPK1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL6657643 | 0.71 | PDPK1 (0.46) | PDPK1SMN1; SMN2KDM4ERIOK2GRM5 | |
| SCHEMBL28165223 | 0.71 | KMT2A (0.42) | PDPK1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL21219440 | 0.70 | — | — | |
| Benzene SCHEMBL28134422 | 0.70 | PDPK1 (0.39) | PDPK1SMN1; SMN2KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1976922-B | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMA CO LTD | 2012-09-05 | — | — | CN | disclosed |
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| CN-1976922-A | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-0050927-B1 | THE PREPARATION OF BETA-LACTAM ANTIBIOTICS | BEECHAM GROUP PLC (GB) | 1985-03-27 | — | — | EP | disclosed |
| US-4473578-A | ACID, ESTER OR SALT DERIVATIVES OF MERCAPTO CARBAPENEMS | BEECHAM GROUP LIMITED (GB) | 1984-09-25 | — | — | US | disclosed |
| US-4438036-A | β-Lactam antibiotics their preparation and their use | BEECHAM GROUP LIMITED (GB) | 1984-03-20 | — | — | US | disclosed |
| EP-0059554-A2 | Beta-lactam antibiotics, a process for their preparation and their use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1982-09-08 | — | — | EP | disclosed |
| EP-0055990-A1 | Beta-lactam antibiotics, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-07-14 | — | — | EP | disclosed |
| EP-0050927-A1 | The preparation of beta-lactam antibiotics | BEECHAM GROUP PLC (GB) | 1982-05-05 | — | — | EP | disclosed |
| EP-0024832-A1 | Beta-lactam antibiotics, their preparation, pharmaceutical compositions containing them and their preparation | BEECHAM GROUP PLC (GB) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | PDPK1 1213/4885SMN1; SMN2 4598/4885KMT2A 3410/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | PDPK1 1213/4885SMN1; SMN2 4598/4885KMT2A 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.